How to Buy Alkermes Stock
Alkermes PLC
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
Alkermes stock last closed at $33.02, down 3.11% from the previous day, and has increased 11.97% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.34 percentage points. Alkermes stock is currently +31.21% from its 52-week low of $25.17, and -9.48% from its 52-week high of $36.48.
There are currently 166.65M shares of ALKS outstanding. The market capitalization of ALKS is $5.50B. In the last 24 hours, 2.06M ALKS shares were traded.
How to Buy Alkermes Stock
Not sure how to invest in Alkermes stock? Here's how.
- Figure out where to buy Alkermes stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Alkermes stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Choose your method of payment and add your info.
- Research Alkermes stock: The Alkermes ticker symbol is ALKS. Is Alkermes stock a good investment? Should you buy shares of ALKS? How do ALKS's underlying business fundamentals look? Do top analysts think Alkermes is a good buy? Why has ALKS's stock price moved recently? (Hint: Our stock market research tools can help you decide if ALKS is a good stock to buy).
- Place your ALKS purchase: Decide if you will purchase ALKS shares at the current market price or use a limit order to purchase ALKS shares at a specific price.
- Get notifications regarding your ALKS investment: Create a watchlist to key updates about your investment in Alkermes stock.
Step 1: Figure out where to buy Alkermes stock
You will need a brokerage account to access the NASDAQ market and buy ALKS stock.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked your brokerage, it's time to fill out some personal info so you are able to invest in ALKS stock today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create your new trading account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've created your account on app for investing, you need to deposit funds:
Check out this video walkthrough to see the process of transferring money into your new investment account.
Step 4: Research Alkermes stock
After you have chosen the best place to buy Alkermes stock, it's very important to evaluate their stock before you invest, so you actually wrap your head around the risk and opportunity.
Alkermes stock data
ALKS Due Diligence Checks
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on ALKS's stock page.
What is the fair value of ALKS stock?
Analysts use many financial metrics, analyses, models, and charts to gauge ALKS's true value.
Using relative valuations methods:
- ALKS may be undervalued based on its P/E ratio of 22.46x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of -159.98x
- ALKS could be overvalued based on its P/B ratio of 3.02x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.6x
You can access more valuation research on ALKS's stock here.
ALKS Financial Summary
Positive Health Checks:
- ALKS earnings of $303.73M is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the ALKS balance sheet.
- ALKS's operating cash flow of $520.75M allows it to safely service it's debt of $70.00M.
- Total ALKS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the ALKS balance sheet.
- ALKS has a low debt to equity ratio of 0.37.
Negative Health Checks:
- ALKS profit margin has gone down from 23.6% to 16.4% in the past year.
Do Wall Street analysts think it's a good time to buy ALKS stock
Out of 9 sell side analysts who give ratings on ALKS, the consensus analyst rating on ALKS is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent ALKS Analyst Upgrades/Downgrades
Joon Lee, a top 2% analyst from Truist Securities maintains ALKS with a strong buy rating and raises their ALKS price target from $50.00 to $55.00, on Nov 17, 2025.
Truist Securities's Joon Lee raised their price target on Alkermes (NASDAQ: ALKS) by 10% from $50 to $55 on 2025/11/17. The analyst maintained their Strong Buy rating on the stock.
Alkermes reported its Q3 2025 earnings on 2025/10/28, but that was not the catalyst for Lee's price target move.
The analyst said their price target move was catalyzed by positive Vibrance-2 results that significantly de-risk the alixorexton program. increase the likelihood of success, and support higher estimates.
The analyst detailed that "cross-trial comparisons show alixorexton outperforming oveporexton in NT2, and the added split-dosing regimen in Phase 3 could further enhance efficacy, with Takeda management viewing the program as representing credible competitive pressure."
David Hoang, a top 9% analyst from Deutsche Bank maintains ALKS with a strong buy rating and lowers their ALKS price target from $55.00 to $45.00, on Nov 13, 2025.
Ami Fadia, a top 1% analyst from Needham maintains ALKS with a buy rating and raises their ALKS price target from $43.00 to $44.00, on Oct 29, 2025.
Uy Ear, a top 22% analyst from Mizuho maintains ALKS with a buy rating and raises their ALKS price target from $40.00 to $45.00, on Oct 27, 2025.
You can dive deeper into what analysts are projecting on the Alkermes stock forecast page.
ALKS Momentum
ALKS Performance Metrics
Last year, ALKS earnings were $241.66M. Over the past 2 year, ALKS's earnings have grown by -17.12% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 9.52%.
Last year, ALKS revenue was $1.48B. During the last five year, ALKS's revenue has gone up by 7.28% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 6.25%.
You can research ALKS's earnings and revenue performance here.
Who is buying/selling ALKS?
In the last 12 months, insiders at ALKS have sold more shares than they have bought.
David Joseph Gaffin, EVP CLO Alkermes Inc. of ALKS, was the latest ALKS insider to sell. They sold $70,315.38 worth of ALKS shares on Apr 6, 2026.
Get more info about who owns ALKS stock here.
Does ALKS stock generate passive income?
No, Alkermes doesn't provide an income stream by paying out dividends.
What others are saying about ALKS
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your ALKS purchase
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually the best for newer investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a specific price, use a limit order.
Click the Open button and eToro will execute the order.
If you want additional help buying stocks on eToro, click the helpful video below:
Step 6: Get notifications regarding your ALKS investment
Now that you own some ALKS stock, you'll want to stay up-to-date on your new investment.
Make a watchlist to get alerted to the latest events about your ALKS stock.
ALKS Feed
How to Buy Stock in Alkermes
To summarize, here are the 6 steps you need to take to buy Alkermes stock right now:
- Figure out where to buy Alkermes stock
- Open a brokerage account
- Deposit money your investment account
- Research Alkermes stock
- Place your ALKS purchase
- Get notifications regarding your ALKS investment
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Alkermes, get started below.
Other "How To" Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.